Promimic AB
AZ BioVenture HUB
c/o Astrazeneca R&D
431 83 MÖLNDAL

www.promimic.com

2017-12-14

Press Release

Promimic HA^{nano} Surface® cleared by the FDA for use on dental implants

Gothenburg – 2017-12-14: Promimic announces that the Food and Drug Administration (FDA) has approved our HA^{nano} Surface for use on dental implants in the USA with our partners S.I.N. The implant line Unitite was first launched in Brazil in 2016 and after this approval S.I.N plans to introduce Unitite on the US market.

This is Promimic's second FDA clearance for the HA^{nano} Surface and our first according to the new FDA legislation for 510(k) medical devices. The clearance will be followed by several FDA submissions during 2018, particularly in the orthopedic area.

HA^{nano} Surface improves osseointegration and bone fusion, which means an improved bone healing around interbody implants of different materials, most common is implants made of titanium. Faster healing promotes faster function, one of the primary objectives for the patient is to get back to normal function with the teeth or a limb, after surgery.

For more information, please contact:
Magnus Larsson, CEO, Promimic AB
magnus.larsson@promimic.com – Phone: +46 709 776477

About Promimic AB

Promimic AB, a VC and privately-owned company, is a world leader in super thin HA surface modification for orthopedic and dental implants that improves osseointegration and bone healing around interbody implants.

Disclaimer